Table 1.
Property | Observed Effects | References |
---|---|---|
Antioxidant | Inhibits of oxidation of low-density lipoproteins (LDL) | 54,55 |
Scavenges nitric oxide; increase inducible nitric oxide synthase expression | 56 | |
Induction of the inducible nitric oxide synthase in macrophages | 57 | |
Increases the ability of LDL to resist oxidation; reduces the plasma levels of total, free, and esterified cholesterol | 58 | |
Antioxidant effects in leukocytes | 59 | |
Lower lipid peroxidation | 57 | |
Anti-inflamatory | Inhibitis lipoxygenase activity and the production of leukotriene B4 | 59 |
Anti-atherogenic | Reduces monocytoid cell adhesion to endothelium and reduces cell adhesion molecule-1 mRNA and protein |
60 |
Anti-cancer | Inhibits growth cancer cells (LN-18, TF-1a, 786-O, T-47D, RPMI-7951, LoVo) | 61 |
Decreases breast cancer cell viability | 62 | |
Reduces the viability of MCF-7 by inducing cell apoptosis | 63 | |
Inhibits cell proliferation (MCF-7, T-24, BBCE) | 64 | |
Anti-microbial | Strong antimicrobial activity against gram-negative and gram-positive bacteria | 65,66 |
Antimicrobial activity against mycoplasma | 67 | |
Able to inhibit the development of: Staphylococcus aureus, Salmonella enteritidis, Bacillus cereus, Klebsiella pneumoniae, Escherichia coli, Campylobacter jejuni, Helicobacter pylori | 68–72 | |
Antiviral | Antiviral against: herpes mononucleosis, hepatis virus, rotavirus, bovine rhinovirus, canine parvovirus, feline leukemia virus | 73 |
Antiviral against: respiratory syncytial virus and para-influenza type 3 virus | 74 |